Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve

ce nature of these pathogens. Specifically, the call aims to establish, pilot and maintain an investigational reserve of Filovirus candidate vaccines against Marburg (MARV) and/or Ebola Sudan (SUDV) to support such preparedness. Readiness for phase 2 and/or phase 2/3 clinical trials of Filovirus vac

cines will be ensured through the advance preparation of key clinical trial activities, including the establishment of an EU-based reserve of those investigational vaccines. Subject to specific conditions being met (such as the occurrence o